Grafa News and Videos — Page 475

RTX (NYSE:RTX) announced that its Raytheon business has been awarded a $1.1 billion contract by the U.S. Navy to produce AIM-9X Block II missiles, along with related hardware and software.

Cineverse (NASDAQ:CNVS) reported fourth quarter fiscal 2026 revenue of $26 million, an increase of 67% from the prior-year period.

PowerBank (NASDAQ:PBK) announced that its US subsidiary, Abundant Solar Power, has been awarded a contract by the United States Department of Defense and the Department of the Army to construct a photovoltaic array, electric vehicle chargers, and associated infrastructure at the Armed Forces Reserve Center in Farmingdale, New York.

Incyte (NASDAQ:INCY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate.

Lilly (NYSE:LLY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Jaypirca (pirtobrutinib) in adults with chronic lymphocytic leukemia (CLL).

Axsome Therapeutics (NASDAQ:AXSM) announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial of solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents.

Fortrea (NASDAQ:FTRE) appointed Jason Knoblauch as Chief Financial Officer, effective July 6, 2026.

Beyond Air (NASDAQ:XAIR) reported fiscal 2026 revenue of $7.7 million, an increase of 107% year over year.

Daiichi Sankyo and AstraZeneca (NYSE:AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Datroway (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Acadia Pharmaceuticals (NASDAQ:ACAD) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older.